HER2 Activation and Endocrine Treatment Resistance in HER2-negative Breast Cancer
Aloran Mazumder1, Stephen Shiao2, Svasti Haricharan1
1Aging and Cancer Immuno-oncology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Abstract:
The lethality of estrogen receptor alpha positive (ER+) breast cancer, which is often considered to have better prognosis than other subtypes, is defined by resistance to the standard of care endocrine treatment. Relapse and metastasis are inevitable in almost every patient whose cancer is resistant to endocrine treatment. Therefore, understanding the underlying causes of treatment resistance remains an important biological and clinical focus of research in this area. Growth factor receptor pathway activation, specifically HER2 activation, has been identified as 1 mechanism of endocrine treatment resistance across a range of experimental model systems. However, clinical trials conducted to test whether targeting HER2 benefits patients with endocrine treatment-resistant ER+ breast cancer have consistently and disappointingly shown mixed results. One reason for the failure of these clinical trials could be the complexity of crosstalk between ER, HER2, and other growth factor receptors and the fluidity of HER2 activation in these cells, which makes it challenging to identify stratifiers for this targeted intervention. In the absence of stratifiers that can be assayed at diagnosis to allow prospective tailoring of HER2 inhibition to the right patients, clinical trials will continue to disappoint. To understand stratifiers, it is important that the field invests in key understudied areas of research including characterization of the tumor secretome and receptor activation in response to endocrine treatment, and mapping the ER-HER2 growth factor network in the normal and developing mammary gland. Understanding these mechanisms further is critical to improving outcomes for the hard-to-treat endocrine treatment-resistant ER+ breast cancer cohort.
Insights
Estrogen receptor-positive breast cancer resistance to endocrine therapy is a major challenge. Understanding growth factor receptor HER2 (human epidermal growth factor receptor 2) interactions is key to developing effective treatments.
Area of Science:
- Oncology
- Molecular Biology
- Endocrinology
Background:
- Estrogen receptor-positive (ER+) breast cancer, despite a generally better prognosis, presents significant lethality due to resistance to endocrine therapy.
- Relapse and metastasis are common in patients with endocrine-resistant ER+ breast cancer, highlighting the urgent need to understand resistance mechanisms.
- Growth factor receptor pathway activation, particularly HER2 (human epidermal growth factor receptor 2), is implicated in endocrine treatment resistance.
Purpose of the Study:
- To investigate the complex interactions between estrogen receptor (ER), HER2, and other growth factor receptors in endocrine-resistant ER+ breast cancer.
- To identify potential stratifiers for HER2-targeted therapies in patients with endocrine-resistant ER+ breast cancer.
- To understand the underlying causes of treatment resistance to improve outcomes for this challenging breast cancer subtype.
Main Methods:
- Analysis of experimental model systems to identify HER2 activation as a mechanism of endocrine resistance.
- Review of clinical trial data evaluating HER2-targeted therapies in endocrine-resistant ER+ breast cancer.
- Emphasis on understudied areas: tumor secretome characterization, receptor activation dynamics, and mapping the ER-HER2 network in mammary gland development.
Main Results:
- Clinical trials targeting HER2 in endocrine-resistant ER+ breast cancer have yielded mixed and disappointing results.
- The complexity of crosstalk between ER, HER2, and other growth factor receptors, along with fluid HER2 activation, complicates the identification of predictive biomarkers.
- Lack of validated stratifiers assayable at diagnosis hinders personalized HER2 inhibition strategies.
Conclusions:
- The failure of current HER2-targeted therapies in endocrine-resistant ER+ breast cancer likely stems from a poor understanding of complex receptor interactions.
- Future research must focus on characterizing the tumor microenvironment and receptor signaling networks to identify effective patient stratification methods.
- Investing in research on tumor secretomes, receptor activation, and the ER-HER2 network is critical for improving outcomes in endocrine-resistant ER+ breast cancer.
More Related Videos
08:28Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
01:27Tumor Immunotherapy